Methods for using and identifying modulators of Delta-like 4

Details Methods for using and identifying modulators of Delta-like 4 Methods for using and identifying modulators of Delta-like 4

2011-03-15

2011-03-15

Bristol, Lynn (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S130100, C424S141100, C424S178100, C514S012200, C530S388100

Reexamination Certificate

active

07906116

ABSTRACT:
In certain embodiments, this present invention provides methods of identifying and using antibodies that act as either agonists or antagonists of Delta-like 4 (Dll4) signaling.

REFERENCES:
patent: 6121045 (2000-09-01), McCarthy et al.
patent: 6262025 (2001-07-01), Ish-Horowicz et al.
patent: 6664098 (2003-12-01), Sakano et al.
patent: 6689744 (2004-02-01), Gao et al.
patent: 6737507 (2004-05-01), Moses et al.
patent: 6783956 (2004-08-01), Ish-Horowicz et al.
patent: 7022499 (2006-04-01), Sakano et al.
patent: 7118890 (2006-10-01), Ish-Horowicz et al.
patent: 2005/0208027 (2005-09-01), Conboy et al.
patent: 2006/0205823 (2006-09-01), Bodmer et al.
patent: 2007/0213266 (2007-09-01), Gill et al.
patent: 2008/0299088 (2008-12-01), Egan et al.
patent: 1 004 669 (2000-05-01), None
patent: WO-96/01839 (1996-01-01), None
patent: WO-97/01571 (1997-01-01), None
patent: WO-98/45434 (1998-10-01), None
patent: WO-00/06726 (2000-02-01), None
patent: WO-02/00690 (2002-01-01), None
patent: WO-02/08284 (2002-01-01), None
patent: WO-02/24221 (2002-03-01), None
patent: WO-03/018799 (2003-03-01), None
patent: WO-03/041735 (2003-05-01), None
patent: WO-03/087159 (2003-10-01), None
patent: 2004/083372 (2004-09-01), None
patent: WO-2007/028110 (2007-03-01), None
patent: WO-2007/070671 (2007-06-01), None
patent: WO-2008/079326 (2008-07-01), None
Adams et al.,Genes Dev., 13:295-306 (1999).
Artavanis-Tsakonas et al.,Science, 284:770-776 (1999).
Benedito R., et al., “Expression of D114 during mouse embryogenesis suggests multiple developmental roles,” Gene Expression Patters, Elsevier, vol. 5, No. 6, Aug. 2005.
Bray, S.J., “Notch signalling: a simple pathway become complex,” Nat. Rev. Mol. Cell. Biol., 7:678-689 (2006).
Carmeliet, P., “Antiogenesis in life, disease and medicine,” Nature, 438:932-936 (2005).
Carmeliet, P., et al., “Abnormal blood vessel development and lethality in embryos lacking a single VEGF allelle,” Nature, 380:435-439 (1996).
Claxton et al., “Periodic Delta-like 4 expression in developing retinal arteries,” Gene Expression Patterns, Elsevier, vol. 5, No. 1, Nov. 2004.
Duarte et al.,Genes Dev., 18:2474-2478 (2004).
Ferrara, N., et al., “Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene,” Nature, 380:439-442 (1996).
Fischer et al.,Genes Dev., 18:901-911 (2004).
Diez, H., et al., “Hypoxia-mediated activation of D114-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate,” Exp Cell Res., 313:1-9 (2007).
Folkman, J., “Fundamental Concepts of the Angiogenic Process,” Current Molecular Medicine, 3:643-651 (2003).
Gale et al., “Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development.” Proceedings of the National Academy of Sciences of the USA, Nov. 2004, vol. 101, No. 45.
Gale et al.,Dev. Biol., 230:151-160 (2001).
Gerety, S.S., et al., “Symmetrical Mutant Phenotypes of the ReceptorEphB4and its Specific Transmembrane Ligandephrin-B2in Cardiovascular Development,” Molecular Cell, 4:403-414 (1999).
Hainaud, P., et al., “The Role of the Vascular Endothelial Growth Factor-Delta-like 4 Ligand/Notch4-Ephrin B2 Cascade in Tumor Vessel Remodeling and Endothelial Cell Functions,” Cancer Research, 66(17):8501-8510 (2006).
Iso et al.,Arterioscler Thromb Vasc Biol., 23:543-553 (2003).
Kertesz, N., et al., “The Soluble Extracellular Domain of EphB4 (sEphB4) Antagonizes EphB4-EphrinB2 Interaction, Modulates Angiogenesis and Inhibits Tumor Growth,” Blood, 107:2330-2338 (2006).
Krebs et al.,Genes Dev., 14:1343-1352 (2000).
Krebs, L.T., et al., “Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants,” Genes & Development, 18:2469-2473 (2004).
Lawson et al.,Dev. Cell, 3:127-136 (2002).
Li et al.,Genomics, 51(1):45-58 (1998).
Liu Zhao-Jun et al., “Regulation of Notchl and D114 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis.” Database medline [online] U.S. National Library of Medicine, Bethesda, MD Jan. 2003, database accession No. NLM12482957.
Lobe et al.,Dev. Biol., 208(2):281-292 (1999).
Lowell et al., “Stimulation of human epidermal differentiation by Delta-Notch signalling at the boundaries of stem-cell clusters,” Current Biology, Current Science, GB, vol. 10, No. 9, May 2000.
Mailhos, C., et al., “Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis,” Differentiation, 69:135-144 (2001).
Mumm and Kopan,Dev. Biol., 228:151-165 (2000).
Nagy and Rossant, Gene Targeting: A Practical Approach, 177-206 (2000).
Noguera, et al., “Expression of Delta-like 4 (D114) ligand in mouse tumor models.” Proceedings of the American Association for Cancer Research Annual Meeting, vol. 46, No. Suppl. S. Apr. 2005.
Risau, W., “Mechanisms of angiogenesis,” Nature, 386:671-674 (1997).
Rossant, J., et al., “Vascular development and patterning: making the right choices,” Curr. Opin. Genet. Dev., 13:408-412 (2003).
Sakai and Miyazaki,Biochem. Biophys. Res. Commun., 237:318-324 (1997).
Scehnet et al., “Inhibition of D114-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion” Blood, 109(11):4753-60. 2007.
Shutter et al.,Genes Dev., 14:1313-1318 (2000).
Shweiki, D., et al., “Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis,” Nature, 359:843-845 (1992).
Uyttendaele et al.,Development, 122:2251-2259 (1996).
Wang, H.U., et al., “Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4,” Cell, 93:741-753 (1998).
Xia, G., et al., “Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer,” J. Urol., 175:1245-1252 (2006).
Yoneya et al.,J. Biochem., 129:27-34 (2001).
Li, Ji-Liang et al, “Delta-like 4 notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo”, Cancer Research, vol. 67(23); pp. 11244-11253 (2007).
Noguera-Troise, I., et al., “Blockade of D114 inhibits tumour growth by promoting non-productive angiogenesis,” Nature, 444(7122):1032-1037 (2006).
Ridgway, J., et al., “Inhibition of D114 signalling inhibits tumour growth by deregulating angiogenesis,” Nature, 444(7122):1083-1087 (2006).

Affiliated with

Also associated with

Rating

Methods for using and identifying modulators of Delta-like 4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for using and identifying modulators of Delta-like 4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for using and identifying modulators of Delta-like 4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2695162